Salivary Gland Neoplasms

Description

This volume in the book series 'Advances in Oto-Rhino-Laryngology' summarizes the current scientific knowledge of salivary gland neoplasms and illustrates recent advances in this clinical area. Chapters are authored by world renowned experts who cover the full breadth of salivary gland neoplasms, from benign to malignant, primary to secondary, and pediatric to adult. This comprehensive review highlights the outcome of treatments as well as the classification, diagnosis, and management of salivary gland neoplasms. It also includes commentary on the future perspective necessary for improvement. All clinicians, both surgical and non-surgical, involved in the diagnosis and treatment of patients with symptoms and diseases of the salivary gland, will find this book indispensable reading. It is also a beneficial educational resource for clinicians, students, and experts in the field.

Informations

• Publié par: S. Karger AG
• Date de parution: 12 avril 2016
• Nombre de lectures: 1
• EAN13: 9783318058024
• Langue: English
• Poids de l'ouvrage: 2 Mo

Extrait

Salivary Gland Neoplasms
Advances in Oto-Rhino-Laryngology
Vol. 78
Series Editor
Patrick J. Bradley Nottingham
Salivary Gland Neoplasms
Volume Editors
Patrick J. Bradley Nottingham
David W. Eisele Baltimore, Md.
49 figures, 33 in color, and 25 tables, 2016
_______________________ Patrick J. Bradley, MBA, FRCSEd, FRCS (Hon), FRACS (Hon), FRCSLT (Hon) Emeritus Honorary Professor, Department ORL-HNS Nottingham University Hospitals Queens Medical Centre Campus, Derby Road Nottingham NG7 2UH (UK)
_______________________ David W. Eisele, MD, FACS Andelot Professor and Director Department of Otolaryngology – Head and Neck Surgery Johns Hopkins University School of Medicine 601 N. Caroline St., Suite 6210 Baltimore, MD 21287-0910 (USA)
Library of Congress Cataloging-in-Publication Data
Names: Bradley, Patrick J., 1949- , editor. | Eisele, David W., editor.
Title: Salivary gland neoplasms / volume editors, Patrick J. Bradley, David W. Eisele.
Other titles: Advances in oto-rhino-laryngology ; v. 78.
Description: Basel ; New York: Karger, [2016] | Series: Advances in oto-rhino-laryngology ; vol. 78 | Includes bibliographical references and index.
Identifiers: LCCN 2016002929| ISBN 9783318058017 (hard cover: alk. paper) | ISBN 9783318058024 (electronic version)
Subjects: | MESH: Salivary Gland Neoplasms--diagnosis | Salivary Gland Neoplasms--pathology | Salivary Gland Neoplasms--therapy
Classification: LCC RC280.S3 | NLM WI 230 | DDC 616.99/4316--dc23 LC record available at http://lccn.loc.gov/2016002929

Bibliographic Indices. This publication is listed in bibliographic services, including Current Contents ® and Index Medicus.
Disclaimer. The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The appearance of advertisements in the book is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
Drug Dosage. The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
© Copyright 2016 by S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland)
www.karger.com
Printed in Germany on acid-free and non-aging paper (ISO 9706) by Kraft Druck GmbH, Ettlingen
ISSN 0065-3071
e-ISSN 1662-2847
ISBN 978-3-318-05801-7
e-ISBN 978-3-318-05802-4
Contents
Preface
Bradley, P.J. (Nottingham); Eisele, D.W. (Baltimore, Md.)
Classification of Salivary Gland Neoplasms
Bradley, P.J. (Nottingham)
Frequency and Histopathology by Site, Major Pathologies, Symptoms and Signs of Salivary Gland Neoplasms
Bradley, P.J. (Nottingham)
Molecular Pathology and Biomarkers
Ha, P. K (San Francicso, Calif.); Stenman, G. (Gothenburg)
Evaluation: Imaging Studies
Kontzialis, M. (Baltimore, Md.); Glastonbury, C.M. (San Francisco, Calif.); Aygun, N. (Baltimore, Md.)
Evaluation: Fine Needle Aspiration Cytology, Ultrasound-Guided Core Biopsy and Open Biopsy Techniques
Howlett, D.C. (Eastbourne); Triantafyllou, A. (Liverpool)
Facial Nerve Monitoring
Guntinas-Lichius, O. (Jena); Eisele, D.W. (Baltimore, Md.)
Surgery for Benign Salivary Neoplasms
Gillespie, M.B. (Charleston, S.C.); Iro, H. (Erlangen)
Recurrent Benign Salivary Gland Neoplasms
Witt, R.L. (Newark, Del.); Nicolai, P. (Brescia)
Prognostic Scoring for Malignant Salivary Gland Neoplasms
Vander Poorten V. (Leuven); Guntinas-Lichius, O. (Jena)
Surgery for Primary Malignant Parotid Neoplasms
Deschler D.G. (Boston, Mass.); Eisele, D.W. (Baltimore, Md.)
Metastatic Cancer to the Parotid
Clark, J. (Sydney, N.S.W.); Wang, S. (San Francisco, Calif.)
Surgery for Malignant Submandibular Gland Neoplasms
Silver, N.L.; Chinn, S.B. (Houston, Tex.); Bradley, P.J. (Nottingham); Weber, R.S (Houston, Tex.)
Surgery for Malignant Sublingual and Minor Salivary Gland Neoplasms
Bradley, P.J. (Nottingham); Ferris, R.L. (Pittsburgh, Pa.)
Facial Reconstruction and Rehabilitation
Guntinas-Lichius, O. (Jena); Genther, D.J.; Byrne, P.J. (Baltimore, Md.)
Management of Regional Metastases of Malignant Salivary Gland Neoplasms
Medina, J. (Oklahoma City, Okla.); Zbären, P. (Bern); Bradley, P.J. (Nottingham)
Indications for Salivary Gland Radiotherapy
Thomson, D.J.; Slevin, N.J. (Manchester); Mendenhall, W.M. (Gainesville, Fla.)
Chemotherapy and Targeted Therapy
Sen, M.; Prestwich, R. (Leeds)
Management of Inoperable Malignant Neoplasms
Kiess, A.P.; Quon, H. (Baltimore, Md.)
Management of Recurrent Malignant Salivary Neoplasms
Merdad, M.; Richmon, J.D.; Quon, H. (Baltimore, Md.)
Salivary Gland Neoplasms in Children and Adolescents
Bradley, P.J. (Nottingham); Eisele, D.W. (Baltimore, Md.)
Distant Metastases and Palliative Care
Glazer, T.A.; Shuman, A.G. (Ann Arbor, Mich.)
Quality of Life after Salivary Gland Surgery
Wax, M.K. (Portland, Oreg.); Talmi, Y.P. (Tel Hashomer)
Salivary Gland Neoplasms: Future Perspectives
Eisele, D.W. (Baltimore, Md.); Bradley, P.J. (Nottingham)
Author Index
Subject Index
Preface
Salivary gland neoplasms are uncommon, and for the majority of clinicians, exposure to their diagnosis and management is gained over the clinician's lifetime. In 1991, the World Health Organization published that there were 12 recognised benign and 19 malignant primary epithelial salivary gland neoplasms, and a decade later, in 2001, it published an update stating that there were now 13 benign and 24 malignant primary epithelial salivary gland neoplasms. Since that time, a number of ‘new’ primarily malignant primary epithelial salivary gland neoplasms have been described.
This volume on salivary gland neoplasms is considered by the volume editors to be a beneficial educational resource for clinicians involved in the management of patients with salivary gland disorders, especially when considering the possible diagnosis of a salivary gland neoplasm. This volume is composed of twenty-three chapters, each written by world-renowned experts on salivary gland neoplasms. The intent for each chapter was to be concise, with concentration on the advances in this clinical area that have recently been made, while still summarising what is known. This editorial process has minimised duplication of information, except where it has been considered important, and each chapter has a bibliography of relevant publications that might be consulted should additional information be required.
The chapters cover the breadth of salivary gland neoplasms, from the major to the minor salivary glands, from benign to malignant, from primary to secondary, from children to adults, and from recurrent benign to malignant disease, and describe management of local regional metastasis, reconstructive procedures following radical parotidectomy, indications for radiotherapy, usage of chemotherapy and targeted therapy, management of distant metastasis and palliative care, quality of life and methods of prognostic scoring for malignant salivary gland neoplasms. The final chapter presents the volume editors’ comments on the future perspective necessary to improve treatment outcomes and patients’ quality of life.
Patrick J. Bradley , MBA, FRCS, Nottingham, UK David W. Eisele , MD, FACS, Baltimore, Md., USA
Bradley PJ, Eisele DW (eds): Salivary Gland Neoplasms. Adv Otorhinolaryngol. Basel, Karger, 2016, vol 78, pp 1-8 (DOI: 10.1159/000442119)
______________________
Classification of Salivary Gland Neoplasms
Patrick J. Bradley
School of Medicine, The University of Nottingham, Nottingham University Hospitals, Queens Medical Centre Campus, Nottingham, UK
______________________
Abstract
Presently, there is no universal ‘working’ classification system acceptable to all clinicians involved in the diagnosis and management of patients with salivary gland neoplasms. The most recent World Health Organization Classification of Tumours: Head and Neck Tumours (Salivary Glands) (2005) for benign and malignant neoplasms represents the consensus of current knowledge and is considered the standard pathological classification based on which series should be reported. The TNM classification of salivary gland malignancies has stood the test of time, and using the stage groupings remains the current standard for reporting treated patients’ outcomes. Many developments in molecular and genetic methods in the meantime have identified a number o